Home > Boards > US OTC > Biotechs >

Nuo Therapeutics, Inc. (AURX)

AURX RSS Feed
Add AURX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 3/14/2019 2:05:41 PM - Followers: 13 - Board type: Free - Posts Today: 0

Nuo Therapeutics, Inc. (OTCQX: AURX)

Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1987 and is based in Gaithersburg, Maryland.
 
Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies within the emerging opportunities of a changing healthcare landscape.
 
http://www.nuot.com/
 

About Us

Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies within the emerging opportunities of a changing healthcare landscape.

Vision for Change

Through bold leadership, better clinical solutions, and products that add true value to a patient’s health, we aim to offer more effective and efficient therapies for healing.

Advancing Wound Care

Nuo Therapeutics’ flagship product, Aurix™, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. It is the only therapy of its kind that is FDA-cleared for use on ulcers and wounds of all types.

 

Management

Peter A. Clausen, Ph.D., Chief Science Officer
 

Peter A. Clausen, Ph.D., Chief Science Officer

Dr. Clausen joined Nuo Therapeutics in September 2008 and has more than 20 years of experience in the biotechnology industry. Prior to joining Nuo Therapeutics, Dr. Clausen was a founding member and Vice President of Research and Development at Marligen Bioscience, where he developed and commercialized innovative genomic and protein analysis products for the life sciences market. Dr. Clausen was the Manager of New Purification Technologies at Life Technologies and the Invitrogen Corporation. He also has significant experience within the commercial biotechnology industry developing peptide and small molecule therapeutics for application in the areas of inflammatory mediated disease and stem cell transplantation. He completed his post-doctoral training at the Laboratory of Molecular Oncology at the National Cancer Institute where his research efforts focused in the areas of oncology, hematopoiesis, and gene therapy. Dr. Clausen earned his PhD in Biochemistry from Rush University in Chicago and a Bachelor of Science degree in Biochemistry from Beloit College.

 
David E. Jorden, CPA, Chief Executive Officer & Chief Financial Officer

David E. Jorden, CPA, Chief Executive Officer & Chief Financial Officer

David E. Jorden has been Chief Executive Officer and Chief Financial Officer of the Company effective July 1, 2016 after serving as Acting CEO since January 8, 2016 and Acting CFO since May 2015. Mr. Jorden also serves as Acting Secretary of the Company, and has served on the Board of Directors since October 2008 and was Executive Chairman from February 2012 to May 2015. From 2003 to 2008, he was with Morgan Stanley’s Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a MBA from Northwestern University’s Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr.Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA) where he has held the position of Acting Chief Financial Officer since August 2012. He is also on the board of a private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs). Mr. Jorden brings his experience and expertise in the areas of capital raising, investor relations, financial management and analysis, and business strategy to the Board and the Company.




Board of Directors
 

 

David E. Jorden, CPA, Chief Executive Officer & Chief Financial Officer

David E. Jorden has been Chief Executive Officer and Chief Financial Officer of the Company effective July 1, 2016 after serving as Acting CEO since January 8, 2016 and Acting CFO since May 2015. Mr. Jorden also serves as Acting Secretary of the Company, and has served on the Board of Directors since October 2008 and was Executive Chairman from February 2012 to May 2015. From 2003 to 2008, he was with Morgan Stanley’s Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a MBA from Northwestern University’s Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr.Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA) where he has held the position of Acting Chief Financial Officer since August 2012. He is also on the board of a private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs). Mr. Jorden brings his experience and expertise in the areas of capital raising, investor relations, financial management and analysis, and business strategy to the Board and the Company.

 

Paul D. Mintz, MD

Paul D. Mintz, MD was elected to the Nuo Therapeutics, Inc. Board of Directors, effective April 7, 2017. Dr. Mintz is currently the Senior Vice President and Chief Medical Officer of Verax Biomedical. Prior to joining Verax Biomedical in early 2016, Dr. Mintz served as Director, Division of Hematology Clinical Review, Office of Blood Research and Review, Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration. Prior to that, for more than 30 years, Dr. Mintz was a member of the faculty of the University of Virginia School of Medicine, where he was a tenured Professor of Pathology and Internal Medicine. He also served as Vice-Chair of Pathology and Chief of the Division of Clinical Pathology, and as Medical Director of the Clinical Laboratories and Transfusion Medicine Services at the University of Virginia Health System. In addition, Dr. Mintz served as Co-Medical Director of Virginia Blood Services. Dr. Mintz is a former President of the American Association of Blood Banks (AABB), served on the AABB’s Board of Directors for nine years, and was a member of and chaired numerous AABB committees. Dr. Mintz is a recipient of the AABB’s John Elliott Memorial Award. He has also served as a member of the Board of Trustees of the National Blood Foundation. Dr. Mintz is the recipient of a Transfusion Medicine Academic Award from the National Heart, Lung and Blood Institute, and was an inaugural inductee into the National Blood Foundation Hall of Fame. He also served as a member of the Medicare Coverage Advisory Committee of the Centers for Medicare and Medicaid Services (CMS). Dr. Mintz is author or co-author of more than 100 articles and editorials spanning clinical practice, blood safety and the evaluation of new transfusion medicine technologies, and has designed and served as principal investigator for numerous clinical trials. He is the sole editor of all three editions of Transfusion Therapy: Clinical Principles and Practice (AABB Press) and has served on several journal editorial boards. Dr. Mintz earned his BA in Philosophy from the University of Rochester and received his MD with honors from the University of Rochester School of Medicine. Dr. Mintz brings considerable knowledge of platelet biology and transfusion medicine, along with senior regulatory and reimbursement experience to Nuo Therapeutics, and will be enormously valuable as the company strives to advance the Aurix System toward broader commercialization in the large and growing chronic wound care market.

C. Eric Winzer

C. Eric Winzer has served as Director since January 30, 2009. Mr. Winzer has over 30 years of experience in addressing diverse financial issues including raising capital, financial reporting, investor relations, banking, taxation, mergers and acquisitions, financial planning and analysis, and accounting operations. Mr. Winzer has been the Chief Financial Officer at Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company, since May 2015. From June 2009 to April 2015 Mr. Winzer served as the Principal Accounting Officer, Senior Vice President of Finance, and Chief Financial Officer for OpGen Inc. (OPGN), a precision medicine company that went public in May 2015. Before his tenure with OpGen Inc., Mr. Winzer held multiple executive positions at Avalon Pharmaceuticals, Inc. (AVRX), a NASDAQ listed biotechnology company, including serving as its Chief Financial Officer and Executive Vice President, Principal Accounting Officer, and Secretary. Before joining Avalon Pharmaceuticals, Mr. Winzer held numerous senior financial positions over twenty years at Life Technologies Corporation (LIFE) (now part of Thermo Fisher Scientific (TMO)) and its predecessor companies, Invitrogen (IVGN) and Life Technologies, Inc. (LTEK). From 1980 to 1986, Mr. Winzer held various financial positions at Genex Corporation. Mr. Winzer has been an Independent Director at Nuo Therapeutics (f/k/a Cytomedix, Inc.) since January 30, 2009. Mr. Winzer holds a B.A. in Economics and Business Administration from Western Maryland College (now, McDaniel College) and an M.B.A. from Mount Saint Mary's University. Mr. Winzer was chosen to serve as a director of the Company in part because of his executive experience in the life sciences industry and his substantial financial knowledge and expertise.

Lawrence S. Atinsky

Lawrence S. Atinsky has served as a director since May 5, 2016. Mr. Atinsky is a Partner at Deerfield Management Company, LP (“Deerfield Management”), a healthcare investment firm focused on advancing healthcare through investment, information and philanthropy. He primarily focuses on the firm’s structured transactions and private equity investments. Prior to joining Deerfield Management, Mr. Atinsky was a partner of Ascent Biomedical Ventures, a healthcare focused private equity firm investing in early-stage biomedical and medical device companies. He has over 18 years of experience investing in healthcare companies and currently serves on the Board of FluoroPharma Medical, Inc. Mr. Atinsky earned a J.D. from New York University School of Law and B.A. degrees in Political Science and Philosophy from the University of Wisconsin-Madison, cum laude. Deerfield Management’s affiliates are currently the sole holders of our Series A Preferred Stock and Mr. Atinsky serves as their designee to our Board of Directors under the Certificate of Designations for our Series A Preferred Stock.

Scott M. Pittman

Scott M. Pittman has served as a director since May 5, 2016. Mr. Pittman has over 30 years in Hospital Executive management. He is a Chief Operating & Business Development Officer for Buchanan General Hospital, a Registered Representative with Calton & Associates, and a Principal of Hospital CEO Associates. He has served as CEO Florida Hospital Zephyrhills, FL, in senior executive positions with Adventist Health Systems, and in various hospital executive positions in southern West Virginia. Mr. Pittman has developed several multimillion dollar hospital and program service expansions, and healthcare entity acquisitions and mergers, and has served on numerous state and regional health planning organizations. He is a Magna cum Laude graduate of Southwestern Adventist University with B.S. & B.A. Degrees in Business and Religion, and a Masters of Hospital Administration from Medical College of Virginia. Mr. Pittman was chosen to serve as a director of the Company in part because of his extensive experience as a hospital executive.

 



The Aurix System™
 

About Aurix™

Aurix™ is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms to jumpstart the natural healing process.

Broaden Your Reach

Aurix is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (DFU, pressure, VLU, etc.) and all severities (partial thickness, full thickness, and complex wounds).

Aurix can be used successfully on patients with:

  • Tunneling
    Sinus tracts
    Bone and tendon exposure
    Hardware exposure

Flexibility for Patients and Providers

Aurix is effective at all stages of wound care for non-healing wounds, allowing providers more treatment flexibility across a broader range of patients.

 

About Aurix™

Aurix™ is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms to jumpstart the natural healing process.

Broaden Your Reach

Aurix is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (DFU, pressure, VLU, etc.) and all severities (partial thickness, full thickness, and complex wounds).

Aurix can be used successfully on patients with:

  • Tunneling
    Sinus tracts
    Bone and tendon exposure
    Hardware exposure

Flexibility for Patients and Providers

Aurix is effective at all stages of wound care for non-healing wounds, allowing providers more treatment flexibility across a broader range of patients.

Aurix

Harnessing the body’s natural healing power leads to fewer applications and less time-to-heal.

For more information visit www.AurixSystem.com

Video-Thumb

 

 

Nuo Therapeutics is committed to delivering the highest quality solutions in biodynamic tissue repair.

For more information about our company or our products, please contact or fill out the form on www.nuot.com/contact/

Corporate Offices
207A Perry Parkway, Suite 1
Gaithersburg, MD 20877

Nashville Office
618 Church St., Suite 305
Nashville, TN 37219

Phone
1.866.298.6633

Fax
1.240.499.2690

Email
info@nuot.com




 
AURX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AURX News: L'OCRCVM permet la reprise de la négociation - AURX 02/28/2019 04:09:00 PM
AURX News: IIROC Trading Resumption - AURX 02/28/2019 04:08:00 PM
AURX News: Current Report Filing (8-k) 01/15/2019 05:03:20 PM
AURX News: Current Report Filing (8-k) 01/03/2019 04:19:38 PM
AURX News: Statement of Changes in Beneficial Ownership (4) 01/03/2019 04:09:36 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#133   Anybody here??? TILIS 03/14/19 02:05:41 PM
#132   Big discrepancy between the Bid and Ask. TILIS 02/05/19 05:58:15 PM
#131   Lots of buzz here, lets keep that momentum empiricalONE 01/28/19 04:30:42 AM
#130   Any news? TILIS 01/23/19 03:15:43 PM
#129   I really hope so. TILIS 01/17/19 04:42:45 PM
#128   with all the insider buying and the news, zoonall 01/17/19 01:07:52 PM
#127   any back up plan here zoonall 01/16/19 11:24:02 PM
#126   I hope AURX will find a solution not TILIS 01/16/19 12:57:27 PM
#125   It doesn't look good, but i don't know zoonall 01/16/19 12:55:05 AM
#124   I believe this should work. Limey42 01/16/19 12:14:06 AM
#123   i cant pull up the press release, can zoonall 01/15/19 11:26:05 PM
#122   Not a good press release :( Limey42 01/15/19 06:36:31 PM
#121   AURX clear manipulation today, but I'm banking on G-Schmoney 01/14/19 02:32:27 PM
#120   $AURX multiple form 4s out recently, insiders own G-Schmoney 01/13/19 09:28:41 PM
#119   AURX just amazing DD G-Schmoney 01/13/19 02:19:08 PM
#118   $AURX Next stop easily 20 cents. After that, BrandonZelfer 01/13/19 12:19:42 PM
#117   $AURX 100% ON LOW VOLUME??? What does G-Schmoney 01/13/19 12:01:25 AM
#116   $AURX is about to blow the roof off G-Schmoney 01/12/19 11:24:32 PM
#115   AURX traders are super slow on the OTC, G-Schmoney 01/12/19 11:16:23 PM
#114   EXACTLY!!! LOL. Insiders own 70% of the shares, AAAAMHIM 01/12/19 06:24:47 PM
#113   Up 100% friday and no following here? Something empiricalONE 01/12/19 05:33:46 PM
#112   No one is in her yet. NICE TO AAAAMHIM 01/12/19 03:41:34 PM
#111   $AURX Who else is in this? I just BrandonZelfer 01/12/19 03:13:01 PM
#110   REMEMBER THAT AURX ONLY HAS A ....WAIT FOR AAAAMHIM 01/12/19 09:23:53 AM
#109   Yes that's amazing without a doubt. AURX AURX AAAAMHIM 01/12/19 09:15:33 AM
#108   IF YOU DIDNT KNOW. $AURX THE FIRST platelet & AAAAMHIM 01/12/19 08:47:28 AM
#107   $AURX new MM NORT on L2 AAAAMHIM 01/12/19 08:44:13 AM
#106   (OTCPK:AURX) is looking for acquisitions. Nuo Therapeutics may AAAAMHIM 01/12/19 08:42:39 AM
#105   AURX we believe the storm has passed the AAAAMHIM 01/12/19 08:41:00 AM
#104   AURX only 9.8M Float and insiders own 70% G-Schmoney 01/11/19 09:15:41 AM
#103   So yeah, just verified...... multiple form 4s all G-Schmoney 01/11/19 09:01:26 AM
#102   $AURX 7 filings in ONE DAY?? I G-Schmoney 01/10/19 07:45:41 AM
#101   $AURX big time player in a huge multi G-Schmoney 01/09/19 09:18:34 PM
#100   Charles E. Sheedy, CFA  Senior Vice President  Portfolio Management  Investmen AAAAMHIM 01/05/19 01:07:08 PM
#99   $AURX .09 FLOAT 1.8M (not a misprint). WOW. AAAAMHIM 01/05/19 01:06:27 PM
#98   Charles E. Sheedy, CFA  Senior Vice President  Portfolio Management  Investmen AAAAMHIM 01/05/19 01:05:13 PM
#97   AURX //www.nuot.com/  http://aurixsystem.com/for-patients/  https://vimeo.com AAAAMHIM 01/05/19 01:04:36 PM
#96   $AURX INSIDER bought 3.5 MILLION shares! http://insideri.com/1683332_00016831681 AAAAMHIM 01/05/19 11:00:03 AM
#95   $AURX INSIDER bought 5.2 million shares!! http://insideri.com/1005483_0000899243 AAAAMHIM 01/05/19 10:59:08 AM
#94   $AURX 0885 WHY DO INSIDERS OWN OVER 72% AAAAMHIM 01/05/19 10:58:18 AM
#93   AURX~~133%% up m1999 01/03/19 02:04:07 PM
#92   AURX ~~600k CASH ,AURX~~As of November 12, 2018, we m1999 01/03/19 12:51:09 PM
#91   AURX~~As of November 12, 2018, we had cash m1999 01/03/19 12:48:18 PM
#90   AURX~~FLOAT 1.8M m1999 01/03/19 12:35:00 PM
#89   AURX~~23,7M O/S m1999 01/03/19 12:32:01 PM
#88   AURX~~.05/.20 crazy thih on L2 m1999 01/03/19 12:31:14 PM
#87   AURX~~INSIDER BUYING CRAZYY m1999 01/03/19 12:08:38 PM
#86   Are you talking about AURX? TILIS 12/20/18 01:54:13 PM
#85   Pull certs rodgranite 12/20/18 03:36:31 AM
#84   Anybody here? TILIS 04/12/18 04:18:14 PM
PostSubject